Full Disclosure And Terms Of Research

Everlife Capital is a research newsletter. That is it.

Everything I publish is for informational and educational purposes only. Nothing on Everlife Capital is a recommendation or solicitation to buy, sell, or hold any security. I am not offering investment advisory services, portfolio management, brokerage services, legal advice, tax advice, or financial planning.

I am not a registered investment adviser, broker dealer, or financial planner.

What I publish reflects my personal opinions, research process, and judgment. It does not consider your personal financial situation, goals, liquidity needs, tax status, or risk tolerance. You should do your own research and consult qualified professionals before making any financial, legal, tax, or medical decisions.

Nothing on Everlife Capital is an offer to sell, or a solicitation of an offer to buy, any security, investment product, or advisory service.

If I ever launch a fund, syndicate, or investment vehicle in the future, it will be offered only through the appropriate legal documents and only to eligible investors where permitted by law.

To be crystal clear, Everlife Capital Fund I is a hypothetical model portfolio (paper portfolio). It is not an actual fund, and I am not managing outside capital through it.

The performance shown is tracked for research and educational purposes based on the methodology I describe. It is not actual client performance and should not be interpreted as such.

Hypothetical and model performance has important limitations. It may not reflect real world execution, fees, commissions, slippage, taxes, liquidity constraints, position sizing constraints, timing differences, or the psychological difficulty of holding volatile positions. Real results will differ, sometimes materially.

I show wins and losses because transparency matters, but model results are still model results.

I believe in skin in the game, and I may personally own securities or other interests related to companies, sectors, or themes I discuss.

That means I may have a financial interest in some of the ideas I write about, including long positions and, where legally permitted and disclosed, short exposure.

Here is how I handle that:

If I hold a position in a company featured in a post, I will clearly disclose that fact in the post.

I generally avoid trading a security mentioned in a Deep Dive for 48 hours before and after publication.

I may change my views at any time, and I am not obligated to provide real time updates when I buy, sell, or rebalance personal positions unless I choose to do so.

I work hard to be accurate and thoughtful, but I cannot guarantee that every source, dataset, filing, or third party statement is complete, current, or error free.

Markets move fast. Science evolves. Companies change. Management teams revise plans. Regulators act. Trials fail. New data appears.

Any estimates, projections, probabilities, scenarios, or forward looking statements are opinions, not promises.

I do not guarantee returns, outcomes, timelines, or accuracy, and I am not responsible for losses resulting from reliance on this content.

Everlife Capital covers longevity science, biotech, and related technologies. When I discuss topics like aging mechanisms, biomarkers, disease pathways, or potential lifespan and healthspan impact, I am discussing research, hypotheses, and early evidence, not giving medical advice.

I am not a doctor, and I am not providing medical diagnosis, treatment, or personalized health recommendations.

Many interventions discussed in longevity research are experimental. Most early stage biotech programs fail. Preclinical findings often do not translate to humans. Early clinical results may not hold up in later trials.

Nothing on Everlife Capital should be used as a substitute for medical advice from a licensed healthcare professional.

Investing in biotech, especially small cap biotech and private startups, is highly speculative and high risk.

These companies may have limited revenue or no revenue, may depend on financing, and may lose significant value based on trial results, regulatory decisions, or capital market conditions.

You can lose part of your investment or all of it. In some cases, losses can happen very quickly.

Do not invest money you cannot afford to lose.

As of the date of this post, my research is independently produced and supported by subscribers unless I clearly state otherwise.

If that ever changes, I will clearly and prominently disclose any material connection, including paid sponsorships, consulting relationships, affiliate links, referral fees, free products, or other compensation.

I will label compensated content in a way that is easy to notice and understand, such as:

[AD]
[SPONSORED]
[PAID PARTNERSHIP]
[AFFILIATE LINK]

No hidden deals. No undisclosed compensation.

If Everlife Capital ever includes testimonials, endorsements, quotes, or third party praise, they may not be representative of everyone’s experience and should not be interpreted as a guarantee of results.

If there is any material connection to the person or entity providing that endorsement, I will disclose it clearly.

I may update this disclosure and terms page from time to time as Everlife Capital evolves. The latest posted version is the one that applies to current content unless otherwise stated.